Fluoxetine and ketamine trigger the p75NTR proteolytic pathway and enhance extinction memory and brain plasticity through p75NTR.

antidepressants binding extinction memory fluoxetine ketamine neuroplasticity p75NTR proteolysis proBDNF

Journal

Biological psychiatry
ISSN: 1873-2402
Titre abrégé: Biol Psychiatry
Pays: United States
ID NLM: 0213264

Informations de publication

Date de publication:
28 Jun 2024
Historique:
received: 22 03 2024
revised: 08 06 2024
accepted: 24 06 2024
medline: 1 7 2024
pubmed: 1 7 2024
entrez: 30 6 2024
Statut: aheadofprint

Résumé

Diverse antidepressants were recently described to bind to TrkB and drive a positive allosteric modulation of endogenous BDNF. Although neurotrophins such as BDNF can bind to the p75 neurotrophin receptor (p75NTR), their precursors are the high affinity p75NTR ligands. While part of an unrelated receptor family capable of inducing completely opposite physiological changes, TrkB and p75NTR feature a cross-like conformation dimer and carry a cholesterol-recognition and alignment consensus in the transmembrane domain. Since such qualities were found crucial for antidepressants to bind to TrkB and drive behavioral and neuroplasticity effects, we hypothesized that their effects might also depend on p75NTR. ELISA-based binding assay and NMR spectroscopy were accomplished to assess whether antidepressants would bind to p75NTR. HEK293T cells and a variety of in vitro assays were used to address whether fluoxetine (FLX) or ketamine (KET) would trigger any α- and γ-secretase-dependent p75NTR proteolysis, and lead to p75NTR nuclear localization. Ocular dominance shift was performed with male and female p75KO mice to study the effects of KET and FLX on brain plasticity, in addition to pharmacological interventions to verifying how p75NTR signaling is important for the effects of KET and FLX in enhancing extinction memory in male WT mice and rats. Antidepressants were found binding to p75NTR, FLX and KET triggered the p75NTR proteolytic pathway and induced p75NTR-dependent behavioral/neuroplasticity changes. We thus hypothesize that antidepressants co-opt both BDNF/TrkB and proBDNF/p75NTR systems to induce a more efficient activity-dependent synaptic competition, thereby boosting the brain ability for remodeling.

Sections du résumé

BACKGROUND BACKGROUND
Diverse antidepressants were recently described to bind to TrkB and drive a positive allosteric modulation of endogenous BDNF. Although neurotrophins such as BDNF can bind to the p75 neurotrophin receptor (p75NTR), their precursors are the high affinity p75NTR ligands. While part of an unrelated receptor family capable of inducing completely opposite physiological changes, TrkB and p75NTR feature a cross-like conformation dimer and carry a cholesterol-recognition and alignment consensus in the transmembrane domain. Since such qualities were found crucial for antidepressants to bind to TrkB and drive behavioral and neuroplasticity effects, we hypothesized that their effects might also depend on p75NTR.
METHODS METHODS
ELISA-based binding assay and NMR spectroscopy were accomplished to assess whether antidepressants would bind to p75NTR. HEK293T cells and a variety of in vitro assays were used to address whether fluoxetine (FLX) or ketamine (KET) would trigger any α- and γ-secretase-dependent p75NTR proteolysis, and lead to p75NTR nuclear localization. Ocular dominance shift was performed with male and female p75KO mice to study the effects of KET and FLX on brain plasticity, in addition to pharmacological interventions to verifying how p75NTR signaling is important for the effects of KET and FLX in enhancing extinction memory in male WT mice and rats.
RESULTS RESULTS
Antidepressants were found binding to p75NTR, FLX and KET triggered the p75NTR proteolytic pathway and induced p75NTR-dependent behavioral/neuroplasticity changes.
CONCLUSION CONCLUSIONS
We thus hypothesize that antidepressants co-opt both BDNF/TrkB and proBDNF/p75NTR systems to induce a more efficient activity-dependent synaptic competition, thereby boosting the brain ability for remodeling.

Identifiants

pubmed: 38945387
pii: S0006-3223(24)01425-2
doi: 10.1016/j.biopsych.2024.06.021
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Cassiano Ricardo Alves Faria Diniz (CRAF)

Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil; Neuroscience Center, HiLIFE, University of Helsinki, Helsinki, Finland; Center for Neuroscience, University of California, Davis - CA, USA. Electronic address: crafd87@gmail.com.

Ana Paula Crestani (AP)

Center for Neuroscience, University of California, Davis - CA, USA; Department of Neuroscience and Behavioral Sciences, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.

Plinio Cabrera Casarotto (PC)

Neuroscience Center, HiLIFE, University of Helsinki, Helsinki, Finland.

Caroline Biojone (C)

Neuroscience Center, HiLIFE, University of Helsinki, Helsinki, Finland; Department of Biomedicine and Translational Neuropsychiatry Unit - Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.

Cecilia Cannarozzo (C)

Neuroscience Center, HiLIFE, University of Helsinki, Helsinki, Finland.

Frederike Winkel (F)

Neuroscience Center, HiLIFE, University of Helsinki, Helsinki, Finland; Current: Centre for Developmental Neurobiology and MRC Centre for Neurodevelopmental Disorders, King's College London, London, UK.

Mikhail A Prozorov (MA)

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia; Lomonosov Moscow State University, Moscow, Russia.

Erik F Kot (EF)

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudny, Russia.

Sergey A Goncharuk (SA)

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudny, Russia.

Danilo Benette Marques (DB)

Department of Neuroscience and Behavioral Sciences, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.

Leonardo Rakauskas Zacharias (LR)

Department of Neuroscience and Behavioral Sciences, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.

Henri Autio (H)

Neuroscience Center, HiLIFE, University of Helsinki, Helsinki, Finland.

Madhusmita Priyadarshini Sahu (MP)

Neuroscience Center, HiLIFE, University of Helsinki, Helsinki, Finland.

Anna Bárbara Borges-Assis (AB)

Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.

João Pereira Leite (JP)

Department of Neuroscience and Behavioral Sciences, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.

Konstantin S Mineev (KS)

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia; Current address: Goethe University Frankfurt, Frankfurt am Main, Germany.

Eero Castrén (E)

Neuroscience Center, HiLIFE, University of Helsinki, Helsinki, Finland. Electronic address: eero.castren@helsinki.fi.

Leonardo Barbosa Moraes Resstel (LBM)

Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil. Electronic address: leoresstel@fmrp.usp.br.

Classifications MeSH